Cutting jobs over device tax is "nonsense," says medtech CEO
Speech therapy devices maker Glottal Enterprises' CEO says that using the 2.3% medical device tax to justify layoffs is "nonsense" and little more than a political strategy to attack the Affordable Care Act.
The medical device tax isn't going to result in lost jobs if industry stakeholders play it right, according to speech therapy device maker Glottal Enterprises' CEO.
In a letter written to the editor of the Syracuse Post-Standard, Martin Rothenberg did the math and concluded that the tax would result in marginal increases in product prices and "zero effect on sales" if the company could successfully market an effective product.
"It would surely not lead us to lay off employees or shift to overseas production," he wrote.